South Korea Fines GSK $2.6M Over Pay-For-Delay Deal

Law360, New York (October 24, 2011, 3:11 PM EDT) -- GlaxoSmithKline PLC was hit Monday with a $2.6 million fine by South Korea's Fair Trade Commission over claims that the global pharmaceutical giant struck an improper deal with Seoul-based Dong-A Pharmaceutical Inc. to keep a generic anti-nausea drug off the market.

In a statement released Monday, the South Korean antitrust regulator said the deal was a settlement of patent litigation between the two companies over the anti-nausea drug Zofran, under which Dong-A agreed not to market a generic version of Zofran in return for exclusive rights...
To view the full article, register now.